KOSDAQElectronic Components109740

DSK

₩2,710▲ 2.46%2026-11-18 close
Market Cap
₩69.7B
Turnover
₩54,462,930
Volume
20K
Shares out.
25.7M
PER
—
PBR
0.7×
EPS
-₩669
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses Persist as Revenue Swings Test DSK's Turnaround

DSK's quarterly revenue swings with FPD and secondary-battery equipment deliveries, operating losses have run for five straight quarters since the third quarter of 2025, and a change of largest shareholder has been in progress.

  1. 1

    Revenue rose 90.7% to KRW 43.2 billion in 2025, yet the operating loss widened to KRW 22.7 billion, with an operating margin of -52.6%.

  2. 2

    The operating loss narrowed to KRW 5.07 billion in the third quarter of 2026 from KRW 8.45 billion a year earlier, while the net loss attributable to controlling shareholders widened to KRW 8.34 billion.

  3. 3

    Revenue in the second quarter of 2026 was KRW 6.43 billion, up 31.1% from the prior quarter and the highest of the last five quarters.

  4. 4

    A share purchase agreement signed on August 6, 2025 is changing the largest shareholder, and the closing date was revised to September 30, 2026.

  5. 5

    PER cannot be calculated because the last four quarters were net losses, and the price-to-book ratio sits below 1x.

02

Business structure

DSK manufactures equipment for FPD (flat panel display) bonding systems and in-line systems, camera module equipment, and secondary-battery equipment. Based on the 2026 semi-annual report, product sales accounted for 59%, Linear and other items for 24%, and other revenue for 17%.

The FPD bonding and in-line systems are produced by only a few companies in Japan and Korea, and two to three companies form an oligopoly for each equipment type, according to the same report.

In secondary batteries, DSK supplies lamination (L&S) equipment for cell assembly to LG Energy Solution, and the value-chain data counts 11 listed companies in the same process. R&D spending in the first half of 2026 was KRW 1.7 billion, or 15.17% of revenue.

Its subsidiary in botulinum toxin products is presented in press coverage as a new business with expected long-term growth. As of December 31, 2023, DSK held a 67.30% stake in that subsidiary. Based on the disclosed data, timing differences in deliveries of order-based revenue may be behind quarterly revenue swings.

A share purchase agreement signed on August 6, 2025 transfers the largest shareholder stake, and the buyer group's planned ownership ratio was disclosed at 25.4%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.8B-₩8.4B−175.5%
2025Q4₩4.4B-₩5.4B−122.4%
2026Q1₩4.9B-₩5.7B−116.7%
2026Q2₩6.4B-₩3.1B−47.6%
2026Q3₩4.7B-₩5.1B−108.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩48.2B-₩13.1B-₩6.5B−27.2%−4.9%31.8%
2023₩71.5B-₩9.7B₩3.3B−13.6%2.5%14.3%
2024₩22.6B-₩19.7B-₩7.8B−87.0%−6.5%24.7%
2025₩43.2B-₩22.7B-₩15.5B−52.6%−14.8%28.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 48.2 billion in 2022 to KRW 71.5 billion in 2023, up 48.2% year on year, which was the largest year of 2022 to 2025. Revenue fell to KRW 22.6 billion in 2024, down 68.3%, the smallest year, and recovered to KRW 43.2 billion in 2025, up 90.7%.

Over the same period the operating loss was KRW 13.1 billion in 2022, KRW 9.71 billion in 2023, KRW 19.7 billion in 2024, and KRW 22.7 billion in 2025, marking four consecutive years of losses.

The loss narrowed in 2023 but widened again in 2024 and 2025, so the operating loss did not shrink even after revenue recovered in 2025. The operating margin was -27.2% in 2022, -13.6% in 2023, -87.0% in 2024, and -52.6% in 2025.

Net income attributable to controlling shareholders turned to a profit of KRW 3.26 billion in 2023, then became a net loss of KRW 7.84 billion in 2024 and a net loss of KRW 15.5 billion in 2025.

Net income including non-controlling interests, a different measure, was KRW 3.58 billion in 2023, a net loss of KRW 11.4 billion in 2024, and a net loss of KRW 19.8 billion in 2025.

Operating cash flow went from KRW 635 million in 2022 to -KRW 10.3 billion in 2023, -KRW 8.44 billion in 2024, and -KRW 10.7 billion in 2025.

Quarterly, the third quarter of 2025 showed revenue of KRW 4.81 billion and an operating loss of KRW 8.45 billion, followed by KRW 4.41 billion and KRW 5.4 billion in the fourth quarter of 2025, and KRW 4.9 billion and KRW 5.72 billion in the first quarter of 2026.

The second quarter of 2026 had the highest revenue of the last five quarters at KRW 6.43 billion and the smallest operating loss at KRW 3.06 billion.

In the third quarter of 2026, revenue was KRW 4.7 billion and the operating loss was KRW 5.07 billion, narrower than a year earlier, while the net loss attributable to controlling shareholders widened to KRW 8.34 billion.

The net loss attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totaled KRW 16.7 billion.

05

Industry analysis

In FPD equipment, bonding and in-line systems are produced only by a few companies in Japan and Korea, and the same report summary describes a market where two to three companies form an oligopoly for each equipment type.

For secondary-battery equipment, the 2026 semi-annual report cited industry data pointing to the maturing of the electric vehicle market, revisions to the US IRA, and reduced subsidies in Europe and China, and expected weaker demand and greater market uncertainty.

This outlook rests on the cited industry data rather than the company's own estimate. The cell assembly process counts 11 listed companies, and DSK's lamination equipment supply relationship is presented with LG Energy Solution.

In this structure, customers' investment schedules can affect the timing of DSK's revenue deliveries. A single contract with HL-GA Battery Company LLC, corrected in a disclosure on December 31, 2025, is one example of order flow on the battery side.

In FPD equipment, the oligopoly structure means that revenue contribution can rise significantly if demand for a given machine recovers.

Quarterly revenue rebounded in the second quarter of 2026 and fell in the third quarter, showing that demand directions across the two equipment groups can diverge from quarter to quarter.

06

Outlook

Revenue rebounded to KRW 6.43 billion in the second quarter of 2026 but fell to KRW 4.7 billion in the third quarter, down 27.0% from the prior quarter and down 2.4% year on year. The operating loss was KRW 3.06 billion in the second quarter and KRW 5.07 billion in the third quarter, so quarterly swings continue.

The single contract with HL-GA Battery Company LLC, corrected in a disclosure on December 31, 2025, is one part of battery-side order flow, but its size and duration are not separated out in the quarterly figures.

A share buyback decision of KRW 1.5 billion was announced on March 14, 2026, and completion of KRW 800 million was disclosed on June 17, 2026.

The change of largest shareholder began with the agreement signed on August 6, 2025, a correction was disclosed on April 1, 2026, and the closing date was changed to September 30, 2026. The cumulative figures for the first three quarters of 2026 follow the third-quarter 2026 quarterly report.

Growth expectations for the botulinum toxin subsidiary have been presented, but its contribution to results cannot be separated from the disclosed figures.

The next checkpoint is the 2026 annual results; if the timing follows the disclosure of 2025 annual results on February 27, 2026, that would fall in late February 2027. The statutory filing deadline for the 2026 annual business report is the end of March 2027.

07

Valuation

PER
—
PBR
0.7×
ROE
-16.5%
EPS
-₩669
BPS
₩3,717
Dividend per share
₩0

Because the net loss attributable to controlling shareholders over the last four quarters totaled KRW 16.7 billion, a PER based on earnings cannot be calculated. The price-to-book ratio is below 1x, a level at which the shares trade at a discount to net assets.

Total equity at the end of 2025 was KRW 115.8 billion, of which the controlling shareholders' stake was KRW 105.2 billion, and total liabilities were KRW 32.9 billion. The debt-to-equity ratio was 31.8% in 2022, 14.3% in 2023, 24.7% in 2024, and 28.4% in 2025.

Earnings moved from a profit attributable to controlling shareholders in 2023 to net losses in 2024 and 2025, with the 2025 loss widening. The dividend yield is close to zero.

On trading volatility, the Korea Exchange designated DSK as an investment-caution stock on June 2, 2026, and as a stock with concentrated trading by a small number of accounts on June 8, 2026.

The June 8 designation reflected an 18.02% share price rise over three days and a buy participation rate of 41.32% by the top ten accounts. With earnings not yet recovered, the multiple is read mainly against net assets and the value of the business.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Quarterly revenue rebound and narrower losses

Revenue in the second quarter of 2026 was KRW 6.43 billion, up 31.1% from the prior quarter, and the operating loss narrowed to KRW 3.06 billion. The third-quarter operating loss of KRW 5.07 billion was also smaller than the KRW 8.45 billion recorded a year earlier.

The decline in operating losses from KRW 8.45 billion in the third quarter of 2025 to KRW 3.06 billion in the second quarter of 2026 can be read as evidence of operating improvement. Whether the improvement continues will be shown in later quarterly figures.

Growth expectations for the toxin subsidiary

Press coverage presents DSK's subsidiary as a new business in botulinum toxin products, with long-term growth expected. Coverage cited that subsidiary's long-term growth as a driver. DSK held a 67.30% stake as of December 31, 2023. If product sales were added to equipment-driven revenue, the revenue mix could change.

Battery customer relationships and equipment base

The lamination equipment supply relationship with LG Energy Solution is presented in value-chain data. A single contract with HL-GA Battery Company LLC was corrected in a disclosure on December 31, 2025. Revenue in 2025 was KRW 43.2 billion, up 90.7% year on year.

FPD equipment sits in an oligopoly structure in which only a few companies in Japan and Korea have production technology.

09

Bear factors

Four years of losses and negative operating cash flow

Operating losses ran for four consecutive years from 2022 to 2025, and the 2025 operating loss of KRW 22.7 billion was larger than the KRW 19.7 billion in 2024. The operating margin in 2025 was -52.6%. Operating cash flow was -KRW 10.3 billion in 2023, -KRW 8.44 billion in 2024, and -KRW 10.7 billion in 2025. The fact that losses and cash outflows did not shrink even in the year revenue recovered is a bearish factor.

Net loss attributable to controlling shareholders widened again

The operating loss narrowed to KRW 5.07 billion in the third quarter of 2026, but the net loss attributable to controlling shareholders widened to KRW 8.34 billion. The net loss attributable to controlling shareholders over the last four quarters totaled KRW 16.7 billion.

Because operating losses and attributable net losses moved in opposite directions, the operating improvement did not translate directly into a smaller net loss.

Demand slowdown outlook and quarterly revenue swings

The 2026 semi-annual report, citing industry data, pointed to weaker secondary-battery equipment demand and greater market uncertainty. Revenue in the third quarter of 2026 was KRW 4.7 billion, down 27.0% from the prior quarter.

Revenue moved from KRW 6.43 billion in the second quarter of 2026 to KRW 4.7 billion in the third, and large variance from delivery timing is a bearish factor.

10

Risk factors

Governance and contract execution

After the August 6, 2025 agreement, the total purchase consideration was revised in a correction disclosed on April 1, 2026, and the closing date was moved to September 30, 2026.

In June 2026 the stock was also designated as an investment-caution stock and as a stock with concentrated trading by a small number of accounts. Whether the change of largest shareholder is completed, and how management is composed afterward, will depend on later disclosures.

Demand and customer concentration

Industry data cited in the 2026 semi-annual report pointed to weaker secondary-battery equipment demand. LG Energy Solution is presented as the supply counterparty in the battery segment. If customers change their investment schedules, quarterly delivery timing and profit flows could shift together.

Financial capacity and litigation

At the end of 2025, total liabilities were KRW 32.9 billion, total equity was KRW 115.8 billion, and the debt-to-equity ratio was 28.4%. Operating cash flow was -KRW 10.7 billion in 2025. The 2026 semi-annual report states that one lawsuit is pending and that its outcome cannot be predicted.

11

What to watch next

  1. Around late February 2027

    Preliminary 2026 annual results. The 2025 annual results were disclosed on February 27, 2026. The checkpoints are revenue, operating loss, and how the operating margin moves from -52.6% in 2025.

  2. End of March 2027

    Filing of the 2026 annual business report, based on the statutory deadline for periodic reports. The checkpoints are confirmed 2026 annual figures and how the change of largest shareholder and governance changes appear in the report.

  3. Mid-May 2027

    First-quarter 2027 results and quarterly report. The first-quarter 2026 results were disclosed on the 15th of the month. The checkpoints are whether losses continue and how the net loss attributable to controlling shareholders compares with KRW 8.34 billion in the third quarter of 2026.

12

Overall view

DSK makes FPD bonding and in-line equipment, camera module equipment, and secondary-battery equipment, and recorded operating losses for four consecutive years from 2022 to 2025. Revenue recovered to KRW 43.2 billion in 2025, but the operating loss widened to KRW 22.7 billion, with an operating margin of -52.6%.

The rebound in second-quarter 2026 revenue and the narrower third-quarter operating loss can be read as improvement signals, but the net loss attributable to controlling shareholders widened to KRW 8.34 billion in the third quarter, bringing the four-quarter total to KRW 16.7 billion.

The outlook for weaker secondary-battery equipment demand and quarterly revenue swings remain business uncertainties.

The change of largest shareholder that began with the August 2025 agreement now has a closing date of September 30, 2026, and the effect of the governance change on business direction will be confirmed through later disclosures.

Growth expectations for the botulinum toxin subsidiary have been reported, but its contribution cannot be separated from the disclosed figures. With the price-to-book ratio below 1x, the recovery of earnings is the key fact to track.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. hedgenaru.com
  2. comp.fnguide.com
  3. vegannews.co.kr
  4. m.news.nate.com
  5. comp.wisereport.co.kr
  6. m.thinkpool.com
  7. m.newsprime.co.kr
  8. stockvery.com
  9. sedaily.com
  10. m.news.nate.com
  11. meerae.ai
  12. judal.co.kr
  13. topstarnews.net
  14. judal.co.kr
  15. judal.co.kr
  16. topstarnews.net
  17. topstarnews.net
  18. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis